Skip to main content
. 2021 Jun 30;9(7):708. doi: 10.3390/vaccines9070708

Figure 1.

Figure 1

Frequency distribution of IgGSP versus days after the second dose of COVID-19 vaccines in LT recipients (a) BNT162b2 (Pfizer-BioNTech); (b) mRNA-1273 (Moderna). DA2D, days after the second dose of COVID-19 vaccines; prior-infected, pink-filled circle (Figure 1a); broken red and blue lines, IgGSP serology assay’s manufacturer-recommended positive cut-off value.